{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T14:59:47Z","timestamp":1782485987862,"version":"3.54.5"},"reference-count":44,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T00:00:00Z","timestamp":1554249600000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Ildong Pharmaceuticals, Co, Ltd"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.clinthera.2019.02.013","type":"journal-article","created":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T02:08:57Z","timestamp":1553134137000},"page":"728-741","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy and Tolerability of Telmisartan\/Amlodipine and Rosuvastatin Coadministration in Hypertensive Patients with Hyperlipidemia: A Phase III, Multicenter, Randomized, Double-blind Study"],"prefix":"10.1016","volume":"41","author":[{"given":"Tae-Seok","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Woon","family":"Rha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok-Yeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae-Gyun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki-Chul","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myung-Ho","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kye-Hoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Cheol","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woo-Sik","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong-Cheon","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moo-Yong","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Hun","family":"Cha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung-Su","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Ho","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki-Dong","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Woon","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Won","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Kyoon","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Seog","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"311","key":"10.1016\/j.clinthera.2019.02.013_bib1","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth Joint National Committee (JNC 8)","volume":"2014","author":"James","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2019.02.013_bib2","doi-asserted-by":"crossref","first-page":"224","DOI":"10.7326\/0003-4819-114-3-224","article-title":"National Education Programs Working Group report on the management of patients with hypertension and high blood cholesterol","volume":"114","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2019.02.013_bib3","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.2337\/diacare.46.10.1594","article-title":"Risk variable clustering in the insulin resistance syndrome. The Framingham Offspring Study","volume":"46","author":"Meigs","year":"1997","journal-title":"Diabetes"},{"key":"10.1016\/j.clinthera.2019.02.013_bib4","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/0002-8703(86)90155-9","article-title":"Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population","volume":"111","author":"Lerner","year":"1986","journal-title":"Am Heart J"},{"issue":"3 Suppl 1","key":"10.1016\/j.clinthera.2019.02.013_bib5","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0033-0620(86)90038-1","article-title":"The effects of drug treatment for hypertension on morbidity and mortality from cardiovascular disease: a review of randomized controlled trials","volume":"29","author":"MacMahon","year":"1986","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.clinthera.2019.02.013_bib6","first-page":"1449","article-title":"Impact of treating hyperlipidemia or hypertension to reduce the risk of death from coronary artery disease","volume":"160","author":"Perreault","year":"1999","journal-title":"CMAJ"},{"key":"10.1016\/j.clinthera.2019.02.013_bib7","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.amjmed.2008.09.038","article-title":"Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials","volume":"122","author":"Wald","year":"2009","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2019.02.013_bib8","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/hr.2013.10","article-title":"Effect of tablets with a combination of telmisartan and amlodipine on patients with hypertension: the Cotalo study","volume":"36","author":"Ohishi","year":"2013","journal-title":"Hypertens Res"},{"key":"10.1016\/j.clinthera.2019.02.013_bib9","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1161\/CIRCULATIONAHA.112.096156","article-title":"Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the National Health and Nutrition Examination Survey, 2001 to 2010","volume":"126","author":"Gu","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2019.02.013_bib10","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/j.clinthera.2012.05.010","article-title":"Pharmacokinetic interaction of telmisartan with s-amlodipine: an open-label, two-period crossover study in healthy Korean male volunteers","volume":"34","author":"Noh","year":"2012","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2019.02.013_bib11","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2165\/11538850-000000000-00000","article-title":"The role of angiotensin receptor blocker and calcium channel blocker combination therapy in treating hypertension: focus on recent studies","volume":"10","author":"Chrysant","year":"2010","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.clinthera.2019.02.013_bib12","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/hr.2009.133","article-title":"Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension","volume":"32","author":"Ishimitsu","year":"2009","journal-title":"Hypertens Res"},{"key":"10.1016\/j.clinthera.2019.02.013_bib13","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2165\/00003495-200666010-00004","article-title":"Telmisartan: a review of its use in the management of hypertension","volume":"66","author":"Battershill","year":"2006","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2019.02.013_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0013694","article-title":"A\u00a0subgroup of high-risk Asians, telmisartan was noninferior to ramipril and better tolerated in the prevention of cardiovascular events","volume":"5","author":"Dans","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2019.02.013_bib15","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1097\/HJH.0b013e3282f76481","article-title":"Pleiotropic effects of telmisartan: still more to come?","volume":"26","author":"Benndorf","year":"2008","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.clinthera.2019.02.013_bib16","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1185\/03007995.2011.597378","article-title":"Telmisartan for the management of patients at high cardiovascular risk","volume":"27","author":"Ruilope","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2019.02.013_bib17","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1365-2710.2011.01295.x","article-title":"Systematic review of the effect of telmisartan on insulin sensitivity in hypertensive patients with insulin resistance or diabetes","volume":"37","author":"Suksomboon","year":"2012","journal-title":"J\u00a0Clin Pharm Ther"},{"key":"10.1016\/j.clinthera.2019.02.013_bib18","doi-asserted-by":"crossref","first-page":"560","DOI":"10.2165\/00003495-199550030-00009","article-title":"Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease","volume":"50","author":"Haria","year":"1995","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2019.02.013_bib19","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1586\/erc.12.155","article-title":"Role of dihydropyridinic calcium channel blockers in the management of hypertension","volume":"11","author":"Coca","year":"2013","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.clinthera.2019.02.013_bib20","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1161\/HYPERTENSIONAHA.107.089763","article-title":"Prevention of stroke and myocardial infarction by amlodipine and angiotensin receptor blockers: a quantitative overview","volume":"50","author":"Wang","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.clinthera.2019.02.013_bib21","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1001\/jama.292.18.2217","article-title":"Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial","volume":"292","author":"Nissen","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2019.02.013_bib22","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ccl.2010.07.001","article-title":"Pathogenesis and clinical physiology of hypertension","volume":"28","author":"Singh","year":"2010","journal-title":"Cardiol Clin"},{"key":"10.1016\/j.clinthera.2019.02.013_bib23","doi-asserted-by":"crossref","first-page":"832183","DOI":"10.5402\/2012\/832183","article-title":"Cardiovascular autonomic response to amlodipine in primary hypertension","volume":"2012","author":"Radjab","year":"2012","journal-title":"ISRN Cardiol"},{"key":"10.1016\/j.clinthera.2019.02.013_bib24","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.clpt.2006.09.003","article-title":"Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance","volume":"80","author":"Neuvonen","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2019.02.013_bib25","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1185\/030079903125002405","article-title":"Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial","volume":"19","author":"McKenney","year":"2003","journal-title":"Curr Med Res Opin"},{"issue":"9429","key":"10.1016\/j.clinthera.2019.02.013_bib26","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0140-6736(04)16616-6","article-title":"Safety and efficacy of rosuvastatin","volume":"364","author":"Olsson","year":"2004","journal-title":"Lancet"},{"issue":"2A","key":"10.1016\/j.clinthera.2019.02.013_bib27","doi-asserted-by":"crossref","first-page":"33A","DOI":"10.1016\/j.amjcard.2005.11.014","article-title":"Justification for the use of statins in primary prevention: an intervention trial evaluating rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?","volume":"97","author":"Mora","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinthera.2019.02.013_bib28","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2165\/11598110-000000000-00000","article-title":"Combination of amlodipine plus angiotensin receptor blocker or diuretics in high-risk hypertensive patients: a 96-week efficacy and safety study","volume":"12","author":"Ma","year":"2012","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.clinthera.2019.02.013_bib29","doi-asserted-by":"crossref","first-page":"e2015010","DOI":"10.4178\/epih\/e2015010","article-title":"Cost-effectiveness analysis of low-density lipoprotein cholesterol-lowering therapy in hypertensive patients with type 2 diabetes in Korea: single-pill regimen (amlodipine\/atorvastatin) versus double-pill regimen (amlodipine+atorvastatin)","volume":"37","author":"Park","year":"2015","journal-title":"Epidemiol Health"},{"key":"10.1016\/j.clinthera.2019.02.013_bib30","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.3346\/jkms.2015.30.12.1800","article-title":"Persistence with antihypertensive medications in uncomplicated treatment-na\u00efve patients: effects of initial therapeutic classes","volume":"30","author":"Ah","year":"2015","journal-title":"J\u00a0Korean Med Sci"},{"key":"10.1016\/j.clinthera.2019.02.013_bib31","unstructured":"Telmisartan 80mg Non-responder Trial. Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT 01222520?term=NCT01222520&rank=1. Accessed March 14, 2019"},{"key":"10.1016\/j.clinthera.2019.02.013_bib33","doi-asserted-by":"crossref","first-page":"329","DOI":"10.5551\/jat.10.329","article-title":"Randomized dose-response study of rosuvastatin in Japanese patients with hypercholesterolemia","volume":"10","author":"Saito","year":"2003","journal-title":"J\u00a0Atheroscler Thromb"},{"key":"10.1016\/j.clinthera.2019.02.013_bib34","doi-asserted-by":"crossref","first-page":"225","DOI":"10.4070\/kcj.2015.45.3.225","article-title":"Additive beneficial effects of valsartan combined with rosuvastatin in the treatment of hypercholesterolemic hypertensive patients","volume":"45","author":"Jang","year":"2015","journal-title":"Korean Circ J"},{"key":"10.1016\/j.clinthera.2019.02.013_bib35","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/00005344-200004000-00006","article-title":"Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia","volume":"35","author":"Borghi","year":"2000","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.clinthera.2019.02.013_bib36","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1081\/JDI-56610","article-title":"Statin therapy helps to control blood pressure levels in hypertensive dyslipidemic patients","volume":"27","author":"Kanbay","year":"2005","journal-title":"Ren Fail"},{"key":"10.1016\/j.clinthera.2019.02.013_bib37","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0002-9149(99)80621-3","article-title":"Effects of pravastatin on cardiovascular reactivity to norepinephrine and angiotensin II in patients with hypercholesterolemia and systemic hypertension","volume":"75","author":"Straznicky","year":"1995","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinthera.2019.02.013_bib38","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/jhh.2013.35","article-title":"Blood pressure-lowering effect of simvastatin: a placebo-controlled randomized clinical trial with 24-h ambulatory blood pressure monitoring","volume":"28","author":"Correa","year":"2014","journal-title":"J\u00a0Hum Hypertens"},{"key":"10.1016\/j.clinthera.2019.02.013_bib39","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1161\/01.HYP.0000259737.43916.42","article-title":"Do statins reduce blood pressure?: a meta-analysis of randomized, controlled trials","volume":"49","author":"Strazzullo","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.clinthera.2019.02.013_bib40","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/jch.12081","article-title":"Antihypertensive effects of statins: a meta-analysis of prospective controlled studies","volume":"15","author":"Briasoulis","year":"2013","journal-title":"J\u00a0Clin Hypertens (greenwich)"},{"key":"10.1016\/j.clinthera.2019.02.013_bib41","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.2147\/DDDT.S112873","volume":"10","author":"Park","year":"2016","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.clinthera.2019.02.013_bib42","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1016\/j.clinthera.2017.10.013","article-title":"A\u00a0randomized, multicenter, double-blind, placebo-controlled study to evaluate the efficacy and the tolerability of a triple combination of amlodipine\/losartan\/rosuvastatin in patients with comorbid essential hypertension and hyperlipidemia","volume":"39","author":"Lee","year":"2017","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2019.02.013_bib43","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.clinthera.2018.03.010","volume":"40","author":"Oh","year":"2018","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2019.02.013_bib44","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1185\/03007990903333389","article-title":"Effectiveness of rosuvastatin in reducing LDL-C and target LDL-C goal attainment in real-world clinical practice","volume":"25","author":"Gandhi","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2019.02.013_bib45","series-title":"Adherence to Long-Term Therapies: Evidence for Action","year":"2003"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819300736?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819300736?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:50:28Z","timestamp":1758963028000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291819300736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S0149291819300736"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.02.013","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Tolerability of Telmisartan\/Amlodipine and Rosuvastatin Coadministration in Hypertensive Patients with Hyperlipidemia: A Phase III, Multicenter, Randomized, Double-blind Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.02.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}